Biljana Mihaljevic

Biljana Mihaljevic

Auto-generated profile, based on publicly available information

Biljana Mihaljevic

Clinical Center of Serbia, Clinic for Hematology, Belgrade + Faculty of Medicine, Belgrade

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
MPMaja Perunicic-Jovanovic
Maja Perunicic-Jovanovic
LJLjubomir Jaković
Ljubomir Jaković
ABAndrija Bogdanovic
Andrija Bogdanovic
OMOlivera Markovic
Olivera Markovic
VCVesna Cemerikic-Martinovic
Vesna Cemerikic-Martinovic
BMBiljana Mihaljevic
Biljana Mihaljevic
Background/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly diagnosed patients with DLBCL, treated with CHOP/R-CHOP (cyclophosphemide doxorubicine, vincristine, prednisone with or without rituximab) regimen, we analyzed the prognostic value of the expression of Ki67 and bcl-2 at diagnosis as well as other standard clinical parameters: International Prognostic Index (IPI), bulky disease, extranodal distribution and lactat dehydrogenase (LDH). Significance was tested according to response rate and overall survival. Results. Univariate survival analysis showed that high IPI had a statistically significant negative influence on overall and event free survival time (log rank, p < 0.01). The log rank test analysis signified that patients with a high proliferative fraction (Ki-67 > 60%) had a worse overall survival rate (OS5y) of 40% compared to those with low proliferation (Ki-67 < 60%) with OS5y of 80% (p < 0.01). There was a clear difference between bcl-2 positivity (treshold 50%) and the achievement of complete remission (66% vs 86% in patients with bcl-2 high and low levels respectively, p < 0.05). In survival analysis, patients with low bcl-2 expression had significantly higher OS5y - 68% compared to those with high bcl-2+ with OS5y 37% (p < 0.05). Multivariate analysis performed by Cox model revealed that IPI > 3, high Ki-67+, bcl-2 positivity had a significant independent prognostic value concerning overall survival (p < 0.05). Conclusion. An initial high IPI score associated with high Ki-67+ and bcl2+ could represent possible predictive factors of poor prognosis, which would help to identify a high risk subgroup of newly diagnosed DLBCL.

1 January 2006 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
BMB. Mihaljevic
B. Mihaljevic
RNR. Nedeljkov-Jancic
R. Nedeljkov-Jancic
VVV. Vujicic
V. Vujicic
DAD. Antic
D. Antic
SJS. Jankovic
S. Jankovic
NCN. Colovic
N. Colovic

1 January 2014 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
TDTijana Dragovic-Ivancevic
Tijana Dragovic-Ivancevic
NKNada Kraguljac-Kurtovic
Nada Kraguljac-Kurtovic
VKVesna Knezevic
Vesna Knezevic
ABAndrija Bogdanovic
Andrija Bogdanovic
BMBiljana Mihaljevic
Biljana Mihaljevic
MGMirjana Gotic
Mirjana Gotic
Introduction. Accurate diagnosis of chronic lymphocytic leukemia (CLL) acquires immunophenotyping by flow cytometry in order to facilitate differential diagnosis between CLL and other mature B-cell neoplasms (MBCN). Objective. The aim of this study was to define immunological profile of CLL cells. Methods. Immunophenotyping by flow cytometry was performed on peripheral blood specimens at diagnosis in the group of 211 patients with de novo MBCN. Results. Absolute count of B-cells was significantly increased in all MBCN patients comparing to healthy control group (p<0.05). B-cell monoclonality was detected in 96% of all MBCN patients, by using surface immunoglobulin (sIg) light chain restriction. B-cell antigens, CD19, CD20, CD22, were expressed with very high frequency in CLL and other MBCN. In comparison with other MBCN, in CLL group, the frequency of expression was higher for CD5 and CD23 (p<0.0001), though lower for FMC7 antigen (p<0.0001). CLL patients were characterized by lower expression patterns of CD20, CD22, CD79b, and sIg (p<0.0001) as well as higher expression pattern of CD5 antigen (p<0.05). Correlation between the final diagnosis of MBCN and values of CLL scoring system showed that the majority of CLL patients (97%) had higher values (5 or 4) whereas the majority of other MBCN patients (96%) had lower score values (0-3). Conclusion. Our results have shown that characteristic immunophenotype which differentiates CLL from other MBCN is defined by following marker combination - CD19+ CD20+low CD22+low CD5+high CD23+ FMC7- CD79b+low sIg+low. CLL score values of 5 or 4 points are highly suggestive for diagnosis of CLL.

9 September 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
AJAna Janjušević
Ana Janjušević
IĆIvana Ćirković
Ivana Ćirković
Rajna MinićRajna Minić
Rajna Minić
GSGoran Stevanović
Goran Stevanović
ISIvan Soldatovic
Ivan Soldatovic
LDLjiljana Markovic- Denic
Ljiljana Markovic- Denic
The predictors of intestinal carriage of vancomycin-resistant Enterococcus spp. (VRE) among high-risk patients in the counties of the Southeast Europe Region are insufficiently investigated, yet they could be of key importance in infection control. The aim of the study was to identify risk factors associated with fecal VRE colonization among high-risk inpatients in university hospitals in Serbia. The study comprised 268 inpatients from three university hospitals. Data on patient demographics and clinical characteristics, length of hospital stay, therapy, and procedures were obtained from medical records. Chi-squared tests and univariate and multivariate logistic regressions were performed. Compared to the hemodialysis departments, stay in the geriatric departments, ICUs, and haemato-oncology departments increased the risk for VRE colonization 7.6, 5.4, and 5.5 times, respectively. Compared to inpatients who were hospitalized 48 h before stool sampling for VRE isolation, inpatients hospitalized 3–7, 8–15, and longer than 16 days before sampling had 5.0-, 4.7-, and 6.6-fold higher risk for VRE colonization, respectively. The use of cephalosporins and fluoroquinolones increased the risk for VRE colonization by 2.2 and 1.9 times, respectively. The age ≥ 65 years increased the risk for VRE colonization 2.3 times. In comparison to the University Clinical Centre of Serbia, the hospital stays at Zemun and Zvezdara University Medical Centres were identified as a protector factors. The obtained results could be valuable in predicting the fecal VRE colonization status at patient admission and consequent implementation of infection control measures targeting at-risk inpatients where VRE screening is not routinely performed.

1 January 2020 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
MTMilena Todorovic-Balint
Milena Todorovic-Balint
JBJelena Bila
Jelena Bila
BBBela Balint
Bela Balint
JJJelena Jelicic
Jelena Jelicic
IDIrena Djunic
Irena Djunic
BMBiljana Mihaljevic
Biljana Mihaljevic
Background/Aim. Autologous stem cell transplants (ASCTs) improve the rate of overall survival (OS) in patients with hematological malignancies such as multiple myeloma (MM) after induction chemotherapy, aggressive non-Hodgkin's lymphomas (NHL), and relapsed, chemotherapy- sensitive Hodgkin's lymphoma (HL). The study aim was to evaluate influence of applied CD34+ cell quantity on clinical outcome, as well as early post-transplant and overall survival (OS) of HL and MM patients following ASCT. Methods. This study included a total of 210 patients (90 HL/120 MM) who underwent ASCT. Stem cell (SC) mobilization was accomplished by granulocyte-colony stimulating factor (G-CSF) 10?16 ?g/kg body mass (bm) following chemotherapy. For proven poor mobilizers, mobilization with G-CSF (16 ?g/kgbm) and Plerixafor (24 or 48 mg) was performed. To our best knowledge, it was the first usage of the Plerixafor in our country in the ASCT-setting. Harvesting was initiated merely at "cut-off-value" of CD34+ cells ? 20 ? 106/L in peripheral blood with "target-dose" of CD34+ cells ? 5 ? 106/kgbm in harvest. The CD34+ cell count and viability was determined using flow cytometry. Results. The majority of HL patients (76.7%) were infused with > 5.0 ? 106/kgbm CD34+ cells, while 68.3% of MM patients were treated by approximately 4.0?5.4 ? 106/kgbm CD34+ dose, respectively. Beneficial response (complete/ partial remission) was achieved in 83.3% (HL) and 94.2% (MM) patients. Among parameters that influenced survival of HL patients with positive response to the therapy, multivariate analysis (pre-ASCT performance status, CD34+ cell quantity applied, rapid hematopoietic, i.e. lymphocyte and platelet recovery) indicated that higher CD34+ cell dose used, along with pre-ASCT performance status correlated with superior event-free survival (EFS) and OS following ASCT. In MM patients, multivariate analysis (renal impairment, infused CD34+ cell quantity, early platelet recovery) indicated that the number of CD34+ cells infused was the most important parameter that influenced both EFS and OS after ASCT. Conclusion. Data obtained in this study undoubtedly confirmed that CD34+ cell dose applied is an independent factor that may contribute to superior clinical outcome and OS of HL and MM patients following ASCT.

1 January 2006 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
BMB. Mihaljevic
B. Mihaljevic
RNR. Nedeljkov-Jancic
R. Nedeljkov-Jancic
VCV. Cemerikic-Martinovic
V. Cemerikic-Martinovic
DBD. Babic
D. Babic
MCM. Colovic
M. Colovic